Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252495 | 0.83 | DPYD (0.34) | DPYDGAA | |
| SCHEMBL5800398 | 0.81 | — | — | |
| SCHEMBL161148 | 0.79 | ATAD2 (0.54) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL2037916 | 0.77 | DPYD (0.46) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL6555485 | 0.77 | DPYD (0.52) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL2584919 | 0.77 | LMNA (0.52) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL5798297 | 0.77 | DPYD (0.46) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL4625879 | 0.77 | ALDH1A1 (0.52) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL31236144 | 0.76 | DPYD (0.45) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL4346481 | 0.76 | DPYD (0.45) | DPYDGAAATAD2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112973464-B | Preparation method and application of photocatalytic sewage treatment membrane | 杭州楠大环保科技有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-112973464-A | Preparation method and application of photocatalytic sewage treatment membrane | 杭州楠大环保科技有限公司 | 2021-06-18 | — | — | CN | claimed |
| CN-104127469-A | New application of olive leaf crude extract and tumor therapeutic drug combined kit thereof | SHANGHAI YUXIAN MEDICAL TECHNOLOGY CO LTD | 2014-11-05 | — | — | CN | claimed |
| CN-1969820-A | Anticancer pharmaceutical composition | JINAN SHUAIHUA MEDICAL TECHNOL (CN) | 2007-05-30 | — | — | CN | claimed |
| CN-1927173-A | Compound recipe anticancer slow release agent comprising tetrazole violet | JINAN SHUAIHUA PHARMACEUTICAL (CN) | 2007-03-14 | — | — | CN | claimed |
| CN-1923173-A | Anti-cancer drugs slow release agent comprising anticancer antibiotics and booster thereof | JINAN KANGQUAN PHARMACEUTICAL (CN) | 2007-03-07 | — | — | CN | claimed |
| CN-1887259-A | Compound anticancer sustained release agent containing clorfarabine | JINAN KANGQUAN MEDICINE SCI TE (CN) | 2007-01-03 | — | — | CN | claimed |
| CN-1887264-A | Slow released compound anticancer prepn containing bendamustine | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2007-01-03 | — | — | CN | claimed |
| CN-1861054-A | Composite slow-releasing anticarcinogen contg. platinum compounds such as sunpla | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-15 | — | — | CN | claimed |
| CN-1857723-A | Slow released anticancer medicine preparation with both amrubicin and its synergist | KANGQUAN MEDICINE SCI TECH CO (CN) | 2006-11-08 | — | — | CN | claimed |
| CN-1857203-A | Compound anticancer sustained-release injection containing blood vessel inhibitor | KANGQUAN MEDICINE SCI TECH CO (CN) | 2006-11-08 | — | — | CN | claimed |
| CN-1850050-A | Compound anticancer slow-release injection containing vascular inhibitor | SHANDONG LANJIN BIOENGINEERING (CN) | 2006-10-25 | — | — | CN | claimed |
| CN-1634584-A | Anti-cancer medicine composition containing antimetabolite | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | claimed |
| EP-0898575-B1 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT DR (US) | 2004-12-29 | — | — | EP | claimed |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-10-16 | — | — | US | claimed |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-03-20 | — | — | US | claimed |
| EP-0898575-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KÖSTER, Hubert (US) | 1999-03-03 | — | — | EP | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
| CN-108341951-B | Dynamic polymer with hybrid cross-linked structure and application thereof | 厦门天策材料科技有限公司 | 2023-06-20 | — | — | CN | disclosed |
| EP-0280741-A1 | MITOMYCIN DERIVATIVES | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | ADAR, RNMT, ATIC | DPYD 519/4885GAA 3190/4885ATAD2 2080/4885 |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | ADAR, RNMT, RRM1 | DPYD 362/4885GAA 2513/4885ATAD2 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.